^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion
    Cancer:Solid Tumor
    Drug:tuxobertinib (BDTX-189) (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A Phase 1/2 Study to Assess the Safety and Antitumor Activity of BDTX-189 in Patients with Advanced Solid Malignancies

    Excerpt:
    ...EGFR or HER2 exon 20 insertion mutation as determined by a validated next-generation sequencing (NGS) test routinely used by each institution using tissue and/or plasma. ...
    Trial ID:
    2020-005492-12
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

    Excerpt:
    ...EGFR or HER2 exon 20 insertion mutation(s) 3....
    Trial ID:
    MasterKey-01
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Black Diamond Therapeutics Press Release
    Title:

    Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

    Published date:
    10/26/2020
    Excerpt:
    Additionally, BDTX-189 demonstrated dose-dependent tumor inhibition and regression in both engineered HER2 S310F tumor models and in EGFR Exon 20 insertion PDX models.